A 63-year-old woman with rheumatic heart disease undergoes echocardiography showing severe mitral stenosis with a valve area of 0.9 cm² and mean gradient of 12 mmHg. She has NYHA class II symptoms. The mitral valve is pliable with minimal calcification and no significant subvalvular disease. There is mild mitral regurgitation and the left atrium is enlarged at 52mm. Transoesophageal echocardiography shows no left atrial appendage thrombus. What is the most appropriate management?
Q92
A 71-year-old man with permanent atrial fibrillation on warfarin (target INR 2.0-3.0) undergoes routine INR monitoring showing a result of 1.6. His previous three INR results over 8 weeks were 2.8, 2.4, and 2.0. He reports good adherence to warfarin 5mg daily. On direct questioning, he mentions starting a new medication from his GP two weeks ago for low mood. Which medication is most likely responsible for the reduced INR?
Q93
A 58-year-old woman presents with 4 hours of chest pain. Her ECG shows ST-segment depression in leads V4-V6 and I, aVL. Troponin T at 6 hours is 186 ng/L (normal <14 ng/L). She is treated with aspirin, ticagrelor, and fondaparinux. Her GRACE score is 156. She undergoes coronary angiography at 18 hours revealing a 90% stenosis in the proximal left anterior descending artery. The cardiologist performs PCI with drug-eluting stent insertion. What is the minimum recommended duration of dual antiplatelet therapy?
Q94
A 54-year-old man with newly diagnosed heart failure and LVEF of 28% is commenced on ramipril, which is gradually uptitrated to 10mg daily. Bisoprolol is then introduced at 1.25mg daily. Three days after starting bisoprolol, he presents with increasing dyspnoea and ankle oedema. Examination reveals bibasal crackles and pitting oedema to knees. Blood pressure is 108/68 mmHg, heart rate 58 bpm. What is the most appropriate management of his beta-blocker therapy?
Q95
A 68-year-old woman undergoes echocardiography for progressive dyspnoea. It demonstrates severe aortic stenosis with a peak velocity of 4.8 m/s, mean gradient of 52 mmHg, and aortic valve area of 0.7 cm². Her left ventricular ejection fraction is 62%. She has exertional chest tightness and has experienced two episodes of exertional presyncope in the past month. What is the most appropriate management?
Q96
A 76-year-old man with permanent atrial fibrillation presents for anticoagulation review. He has a history of hypertension, heart failure (LVEF 38%), and previous TIA 18 months ago. His CHA₂DS₂-VASc score is 6. He has normal renal function (eGFR 68 ml/min/1.73m²) and no history of gastrointestinal bleeding. He is currently not anticoagulated due to previous patient refusal. What is the most appropriate anticoagulation strategy?
Q97
A 45-year-old woman presents with central chest pain radiating to her jaw, lasting 30 minutes and resolving spontaneously. Troponin I at presentation is 8 ng/L (normal <14 ng/L), repeated at 3 hours is 42 ng/L. ECG shows T-wave inversion in leads V3-V6. She is haemodynamically stable. Her GRACE score is calculated as 118. What is the most appropriate management strategy?
Q98
A 72-year-old man presents to the Emergency Department with 90 minutes of severe central chest pain. ECG shows 3mm ST-segment elevation in leads II, III, and aVF with reciprocal changes in the lateral leads. The nearest primary PCI centre is 90 minutes away by ambulance. His blood pressure is 128/76 mmHg and heart rate 88 bpm. What is the most appropriate immediate management?
Q99
A 68-year-old woman with chronic heart failure and left ventricular ejection fraction of 32% is reviewed in clinic. She remains symptomatic (NYHA class II) despite treatment with ramipril 10mg daily, bisoprolol 10mg daily, and furosemide 40mg daily. Her blood pressure is 118/72 mmHg, heart rate 68 bpm and regular, potassium 4.2 mmol/L, and eGFR 58 ml/min/1.73m². What is the most appropriate addition to her treatment regimen?
Q100
A 55-year-old man is diagnosed with hypertension after ambulatory blood pressure monitoring shows a mean daytime blood pressure of 152/96 mmHg. He has no other cardiovascular risk factors and normal renal function. His QRISK3 score is 8%. Lifestyle modifications are discussed. According to NICE guidelines, what is the most appropriate initial pharmacological management?
Cardiology UK Medical PG Practice Questions and MCQs
Question 91: A 63-year-old woman with rheumatic heart disease undergoes echocardiography showing severe mitral stenosis with a valve area of 0.9 cm² and mean gradient of 12 mmHg. She has NYHA class II symptoms. The mitral valve is pliable with minimal calcification and no significant subvalvular disease. There is mild mitral regurgitation and the left atrium is enlarged at 52mm. Transoesophageal echocardiography shows no left atrial appendage thrombus. What is the most appropriate management?
A. Medical management with diuretics and beta-blockers, surgical review if symptoms progress
B. Percutaneous mitral balloon valvuloplasty (Correct Answer)
C. Mitral valve replacement with mechanical prosthesis
D. Mitral valve replacement with bioprosthetic valve
E. Mitral valve repair
Explanation: ***Percutaneous mitral balloon valvuloplasty***- **Percutaneous mitral balloon valvuloplasty (PMBV)** is the **first-line intervention** for symptomatic **severe mitral stenosis** (valve area < 1.5 cm²) when the valve anatomy is favorable.- This patient presents with **severe mitral stenosis** and **NYHA class II symptoms**, along with ideal anatomical features for PMBV, including a **pliable valve**, minimal calcification, no significant subvalvular disease, and no left atrial thrombus.*Medical management with diuretics and beta-blockers, surgical review if symptoms progress*- While diuretics and beta-blockers can help alleviate symptoms of **pulmonary congestion** and control heart rate, they do not address the underlying **mechanical obstruction** of the mitral valve.- For **symptomatic severe mitral stenosis** with favorable anatomy, guidelines recommend definitive intervention rather than simply managing symptoms, as delaying can lead to further cardiac remodeling.*Mitral valve replacement with mechanical prosthesis*- **Mitral valve replacement (MVR)**, especially with a mechanical prosthesis, is typically reserved for patients with **unfavorable valve anatomy** for PMBV or repair, or those with significant concomitant mitral regurgitation.- A mechanical prosthesis necessitates **lifelong anticoagulation** with its inherent risks, which can be avoided if PMBV is a viable option.*Mitral valve replacement with bioprosthetic valve*- Similar to mechanical MVR, a **bioprosthetic valve replacement** is generally considered when the valve is unsuitable for less invasive procedures like PMBV or surgical repair.- Although it obviates the need for long-term anticoagulation, bioprosthetic valves have a finite lifespan due to **structural valve degeneration**, potentially requiring re-operation.*Mitral valve repair*- **Surgical mitral valve repair** (open commissurotomy) is an option for suitable candidates but is a more **invasive procedure** requiring **open-heart surgery** and cardiopulmonary bypass.- **PMBV** is preferred over surgical repair for appropriate patients due to its lower **perioperative risk** and comparable long-term outcomes for severe mitral stenosis.
Question 92: A 71-year-old man with permanent atrial fibrillation on warfarin (target INR 2.0-3.0) undergoes routine INR monitoring showing a result of 1.6. His previous three INR results over 8 weeks were 2.8, 2.4, and 2.0. He reports good adherence to warfarin 5mg daily. On direct questioning, he mentions starting a new medication from his GP two weeks ago for low mood. Which medication is most likely responsible for the reduced INR?
A. Sertraline
B. Amitriptyline
C. St John's Wort (Correct Answer)
D. Fluoxetine
E. Mirtazapine
Explanation: ***St John's Wort***
- **St John's Wort** is a potent **inducer of cytochrome P450 enzymes** (especially **CYP2C9**), which increases the metabolism of **warfarin**, leading to a subtherapeutic **INR**.
- It is a common herbal remedy for **low mood** that patients often start without professional consultation, necessitating specific screening for **herbal supplements**.
*Sertraline*
- **Sertraline** is an **SSRI** that can potentially **inhibit** CYP enzymes, which would logically lead to an **increase** in INR and bleeding risk rather than a decrease.
- SSRIs also increase bleeding risk by inhibiting **serotonin uptake in platelets**, further contradicting the finding of a low INR.
*Amitriptyline*
- **Amitriptyline** is a **tricyclic antidepressant** (TCA) that does not have a clinically significant effect on **warfarin metabolism** or INR levels.
- Its primary side effects are **anticholinergic** (e.g., dry mouth, urinary retention) rather than enzymatic induction.
*Fluoxetine*
- **Fluoxetine** is a strong **CYP2C9 inhibitor**, which would typically **elevate the INR** and increase the risk of over-anticoagulation.
- Similar to other SSRIs, it would not explain a sudden drop in INR from 2.0 to 1.6.
*Mirtazapine*
- **Mirtazapine** has a low potential for **cytochrome P450 interactions** and is generally considered safe to use alongside warfarin without adjusting the dose.
- It acts on **noradrenergic and specific serotonergic receptors** and does not induce the enzymes responsible for clearing warfarin.
Question 93: A 58-year-old woman presents with 4 hours of chest pain. Her ECG shows ST-segment depression in leads V4-V6 and I, aVL. Troponin T at 6 hours is 186 ng/L (normal <14 ng/L). She is treated with aspirin, ticagrelor, and fondaparinux. Her GRACE score is 156. She undergoes coronary angiography at 18 hours revealing a 90% stenosis in the proximal left anterior descending artery. The cardiologist performs PCI with drug-eluting stent insertion. What is the minimum recommended duration of dual antiplatelet therapy?
A. 1 month
B. 3 months
C. 6 months
D. 12 months (Correct Answer)
E. Lifelong therapy
Explanation: ***12 months*** - For patients presenting with **Acute Coronary Syndrome (ACS)**, such as this NSTEMI, the standard recommendation for **Dual Antiplatelet Therapy (DAPT)** is **12 months** regardless of the stent type. - This prolonged duration is essential to reduce the risk of **recurrent ischemic events** and **stent thrombosis** in the high-risk post-ACS period.*1 month* - A **1-month** duration is generally too short for ACS patients and is only considered in extreme cases of **very high bleeding risk** where long-term therapy is life-threatening. - Discontinuing DAPT this early after **drug-eluting stent (DES)** placement in an ACS setting significantly increases the risk of mortality and **myocardial infarction**.*3 months* - **3 months** of DAPT might be an option for patients with stable coronary disease or those at **high bleeding risk**, but it is not the standard for ACS. - In the context of an **NSTEMI** with a high GRACE score, shortening therapy to 3 months would leave the patient under-protected against **ischaemic complications**.*6 months* - While **6 months** is the default duration for DAPT in **stable coronary artery disease** after DES insertion, it is insufficient for ACS management. - Current guidelines strictly preserve the **12-month** recommendation for ACS patients unless there are major **bleeding complications** that necessitate early cessation.*Lifelong therapy* - While **aspirin** should be continued **lifelong** for secondary prevention, DAPT (adding a second agent like Ticagrelor) is not routinely prescribed for life. - **Lifelong DAPT** significantly increases the cumulative risk of major **bleeding episodes** without providing a proven survival benefit over aspirin monotherapy after the initial 12 months.
Question 94: A 54-year-old man with newly diagnosed heart failure and LVEF of 28% is commenced on ramipril, which is gradually uptitrated to 10mg daily. Bisoprolol is then introduced at 1.25mg daily. Three days after starting bisoprolol, he presents with increasing dyspnoea and ankle oedema. Examination reveals bibasal crackles and pitting oedema to knees. Blood pressure is 108/68 mmHg, heart rate 58 bpm. What is the most appropriate management of his beta-blocker therapy?
A. Stop bisoprolol permanently as he cannot tolerate beta-blocker therapy
B. Reduce bisoprolol to 1.25mg on alternate days and review in 1 week
C. Continue bisoprolol at current dose and increase diuretic therapy (Correct Answer)
D. Increase bisoprolol to 2.5mg daily to improve cardiac output
E. Switch from bisoprolol to carvedilol
Explanation: ***Continue bisoprolol at current dose and increase diuretic therapy***- Beta-blockers can cause a transient worsening of heart failure symptoms due to their **negative inotropic effect** during the initial initiation phase.- Guidelines recommend continuing the beta-blocker while managing **fluid overload** with increased **diuretics**, as beta-blockers provide significant long-term **mortality benefit**.*Stop bisoprolol permanently as he cannot tolerate beta-blocker therapy*- Permanent cessation should only occur in cases of severe intolerance, such as **cardiogenic shock** or symptomatic **bradycardia** (usually HR < 50 bpm).- Discarding this disease-modifying therapy prematurely denies the patient a crucial intervention for improving **left ventricular ejection fraction**.*Reduce bisoprolol to 1.25mg on alternate days and review in 1 week*- Reducing the dose is generally reserved for patients with more severe decompensation; in mild cases, managing the **congestive symptoms** is preferred.- **Alternate-day dosing** is not a standard titration strategy for beta-blockers in heart failure management.*Increase bisoprolol to 2.5mg daily to improve cardiac output*- Increasing the dose during an **acute decompensation** phase would likely worsen the patient's heart failure and fluid retention.- Beta-blockers must be **up-titrated slowly** every 2-4 weeks only once the patient is clinically stable and **euvolaemic**.*Switch from bisoprolol to carvedilol*- There is no clinical indication that a switch to **carvedilol** (a non-selective alpha/beta-blocker) would resolve the fluid retention better than **bisoprolol**.- Switching agents at this stage unnecessarily restarts the titration process without addressing the underlying **fluid overload**.
Question 95: A 68-year-old woman undergoes echocardiography for progressive dyspnoea. It demonstrates severe aortic stenosis with a peak velocity of 4.8 m/s, mean gradient of 52 mmHg, and aortic valve area of 0.7 cm². Her left ventricular ejection fraction is 62%. She has exertional chest tightness and has experienced two episodes of exertional presyncope in the past month. What is the most appropriate management?
A. Refer for urgent surgical aortic valve replacement (Correct Answer)
B. Commence bisoprolol and monitor symptoms with annual echocardiography
C. Arrange dobutamine stress echocardiography to assess aortic stenosis severity
D. Refer for transcatheter aortic valve implantation (TAVI) assessment
E. Refer for balloon aortic valvuloplasty
Explanation: ***Refer for urgent surgical aortic valve replacement***- This patient presents with **severe symptomatic aortic stenosis (AS)**, characterized by a **mean gradient of 52 mmHg**, **peak velocity of 4.8 m/s**, and **aortic valve area of 0.7 cm²**, along with classic symptoms like **dyspnoea**, **exertional chest tightness**, and **presyncope**.- In patients with symptomatic severe AS, **surgical aortic valve replacement (SAVR)** is the definitive treatment and significantly improves prognosis, as symptoms like syncope and angina are strong indicators of poor outcomes without intervention.*Commence bisoprolol and monitor symptoms with annual echocardiography*- **Beta-blockers like bisoprolol** are generally **contraindicated or used with extreme caution** in severe AS as they can reduce cardiac output and worsen symptoms by blunting the compensatory heart rate response.- Monitoring symptoms annually with echocardiography is appropriate for **asymptomatic** severe AS, but this patient is **highly symptomatic**, requiring urgent intervention, not just monitoring.*Arrange dobutamine stress echocardiography to assess aortic stenosis severity*- **Dobutamine stress echocardiography** is primarily used to assess **low-flow, low-gradient AS with reduced LVEF** to differentiate true severe AS from pseudo-severe AS.- This patient has **high-gradient AS** (mean gradient 52 mmHg) and a **normal LVEF (62%)**, so the severity of AS is already clearly established without the need for further assessment.*Refer for transcatheter aortic valve implantation (TAVI) assessment*- **TAVI** is an alternative to SAVR, typically preferred for patients with **high surgical risk** or those who are **older (e.g., >75-80 years old)**.- At 68 years old and without specific mention of high surgical risk, **SAVR remains the gold standard** for this relatively younger patient, though a Heart Team discussion is always important.*Refer for balloon aortic valvuloplasty*- **Balloon aortic valvuloplasty** is a **palliative procedure** with high rates of **restenosis** and is generally considered a temporary bridge to definitive treatment or for patients unsuitable for surgery/TAVI.- It is not a definitive long-term solution for symptomatic severe AS in a patient who is likely a good candidate for valve replacement.
Question 96: A 76-year-old man with permanent atrial fibrillation presents for anticoagulation review. He has a history of hypertension, heart failure (LVEF 38%), and previous TIA 18 months ago. His CHA₂DS₂-VASc score is 6. He has normal renal function (eGFR 68 ml/min/1.73m²) and no history of gastrointestinal bleeding. He is currently not anticoagulated due to previous patient refusal. What is the most appropriate anticoagulation strategy?
A. Aspirin 75mg once daily
B. Warfarin with target INR 2.0-3.0
C. Apixaban 5mg twice daily (Correct Answer)
D. Rivaroxaban 15mg once daily
E. No anticoagulation; annual stroke risk does not justify treatment
Explanation: ***Apixaban 5mg twice daily***- With a **CHA₂DS₂-VASc score of 6**, this patient is at high risk for stroke; **Direct Oral Anticoagulants (DOACs)** like apixaban are first-line therapy due to their superior safety profile and predictable pharmacokinetics.- The **standard dose** (5mg BID) is appropriate here as the patient does not meet the criteria for dose reduction (needs 2 of: age ≥80, weight ≤60kg, or creatinine ≥1.5 mg/dL or eGFR <30 mL/min).
*Aspirin 75mg once daily*- Antiplatelet monotherapy is **ineffective for stroke prevention** in atrial fibrillation and is no longer recommended for this purpose.- It carries a significant **bleeding risk** without providing the embolic protection offered by oral anticoagulants.
*Warfarin with target INR 2.0-3.0*- While effective, warfarin is generally second-line to DOACs due to the requirement for constant **INR monitoring** and many dietary/drug interactions.- Evidence from trials like **ARISTOTLE** shows apixaban has a lower risk of **intracranial hemorrhage** and major bleeding compared to warfarin.
*Rivaroxaban 15mg once daily*- This is an **incorrect dose** for this patient; the standard dose for stroke prevention in AF is **20mg once daily**.- The 15mg dose is only indicated if the **eGFR is between 15-49 ml/min**, whereas this patient's renal function is higher (68 ml/min).
*No anticoagulation; annual stroke risk does not justify treatment*- A score of 6 translates to an annual stroke risk of approximately **9.6%**, which far outweighs the risk of major bleeding.- Clinical guidelines strongly recommend anticoagulation for any male with a **CHA₂DS₂-VASc score ≥2** to improve mortality and morbidity.
Question 97: A 45-year-old woman presents with central chest pain radiating to her jaw, lasting 30 minutes and resolving spontaneously. Troponin I at presentation is 8 ng/L (normal <14 ng/L), repeated at 3 hours is 42 ng/L. ECG shows T-wave inversion in leads V3-V6. She is haemodynamically stable. Her GRACE score is calculated as 118. What is the most appropriate management strategy?
A. Aspirin, ticagrelor, fondaparinux, and coronary angiography within 72 hours (Correct Answer)
B. Aspirin, clopidogrel, and conservative management with outpatient stress testing
C. Aspirin, prasugrel, and immediate coronary angiography within 2 hours
D. Aspirin alone and discharge with cardiology follow-up in 2 weeks
E. Aspirin, ticagrelor, fondaparinux, and immediate coronary angiography within 24 hours
Explanation: ***Aspirin, ticagrelor, fondaparinux, and coronary angiography within 72 hours***
- The patient presents with **NSTEMI**, evidenced by typical chest pain, **dynamic troponin elevation**, and **ECG T-wave inversions**.
- A **GRACE score of 118** places her in the **intermediate-risk** category, necessitating **dual antiplatelet therapy** (Aspirin and Ticagrelor), anticoagulation (Fondaparinux), and an **invasive strategy (coronary angiography)** within **72 hours**.
*Aspirin, clopidogrel, and conservative management with outpatient stress testing*
- **Conservative management** and outpatient stress testing are inappropriate for a confirmed **NSTEMI** patient with objective evidence of myocardial injury.
- For ACS, **ticagrelor** or **prasugrel** are generally preferred over **clopidogrel** due to their more potent and consistent antiplatelet effect.
*Aspirin, prasugrel, and immediate coronary angiography within 2 hours*
- **Immediate coronary angiography within 2 hours** is reserved for **very high-risk NSTEMI** patients, such as those with hemodynamic instability or ongoing ischemia, which are not present here.
- While **prasugrel** is an effective P2Y12 inhibitor, the urgency of angiography is not indicated for this **hemodynamically stable, intermediate-risk** patient.
*Aspirin alone and discharge with cardiology follow-up in 2 weeks*
- Discharging a patient with a confirmed **NSTEMI** on **aspirin alone** is dangerously insufficient and would lead to a high risk of adverse cardiovascular events.
- **Dual antiplatelet therapy**, anticoagulation, and an **invasive strategy** are mandatory for NSTEMI, requiring inpatient admission and management.
*Aspirin, ticagrelor, fondaparinux, and immediate coronary angiography within 24 hours*
- The **24-hour angiography window** is recommended for **high-risk NSTEMI** patients, typically those with a **GRACE score >140** or other high-risk features like dynamic ECG changes.
- With a **GRACE score of 118**, this patient is categorized as **intermediate-risk**, making an invasive strategy within **72 hours** the most appropriate and guideline-recommended timeframe.
Question 98: A 72-year-old man presents to the Emergency Department with 90 minutes of severe central chest pain. ECG shows 3mm ST-segment elevation in leads II, III, and aVF with reciprocal changes in the lateral leads. The nearest primary PCI centre is 90 minutes away by ambulance. His blood pressure is 128/76 mmHg and heart rate 88 bpm. What is the most appropriate immediate management?
A. Commence heparin infusion and arrange transfer for angiography the following day
B. Immediate thrombolysis followed by transfer for angiography (Correct Answer)
C. Urgent transfer for primary percutaneous coronary intervention
D. Aspirin, ticagrelor, and arrange urgent inpatient angiography within 72 hours
E. Thrombolysis only if symptoms persist despite optimal medical therapy
Explanation: ***Immediate thrombolysis followed by transfer for angiography***
- For a **STEMI**, primary **PCI** is the preferred strategy only if it can be performed within **120 minutes** of first medical contact; here, a 90-minute transfer time makes fibrinolysis the priority given its immediate availability.
- Following successful **thrombolysis**, the patient should be transferred to a **PCI center** for routine angiography within 2-24 hours to assess for residual stenosis or to perform rescue PCI if reperfusion fails.
*Commence heparin infusion and arrange transfer for angiography the following day*
- This approach is inappropriate for **ST-elevation myocardial infarction (STEMI)**, which requires immediate **reperfusion therapy** to salvage myocardium and improve outcomes.
- Heparin alone is not a primary reperfusion strategy for STEMI, and delaying definitive reperfusion until the next day significantly increases the risk of **major adverse cardiac events**.
*Urgent transfer for primary percutaneous coronary intervention*
- While **primary PCI** is the gold standard for **STEMI**, the 90-minute transfer time likely means the total door-to-balloon time would exceed the recommended **120-minute window** from first medical contact.
- In settings where primary PCI cannot be achieved within the optimal time frame, **fibrinolysis** administered promptly significantly reduces mortality and morbidity.
*Aspirin, ticagrelor, and arrange urgent inpatient angiography within 72 hours*
- This management pathway is reserved for patients with **non-ST-elevation myocardial infarction (NSTEMI)** or **unstable angina**, where there is no complete thrombotic occlusion requiring immediate reperfusion.
- In **STEMI**, the presence of persistent ST-segment elevation indicates total occlusion of a coronary artery, demanding rapid reperfusion (within minutes to hours, not days) to prevent extensive **transmural infarction**.
*Thrombolysis only if symptoms persist despite optimal medical therapy*
- **Thrombolysis** is an emergency reperfusion treatment that should be administered as soon as possible after a **STEMI** diagnosis, as a primary reperfusion strategy, not as a second-line therapy.
- Waiting for
Question 99: A 68-year-old woman with chronic heart failure and left ventricular ejection fraction of 32% is reviewed in clinic. She remains symptomatic (NYHA class II) despite treatment with ramipril 10mg daily, bisoprolol 10mg daily, and furosemide 40mg daily. Her blood pressure is 118/72 mmHg, heart rate 68 bpm and regular, potassium 4.2 mmol/L, and eGFR 58 ml/min/1.73m². What is the most appropriate addition to her treatment regimen?
A. Spironolactone 25mg once daily (Correct Answer)
B. Digoxin 125mcg once daily
C. Ivabradine 5mg twice daily
D. Hydralazine and isosorbide dinitrate
E. Increase furosemide to 80mg daily
Explanation: ***Spironolactone 25mg once daily***
- In patients with **HFrEF** (LVEF ≤ 40%) who remain symptomatic despite optimal doses of **ACE inhibitors** and **beta-blockers**, a **mineralocorticoid receptor antagonist (MRA)** is the next step to reduce mortality.
- This patient satisfies the safety criteria for starting an MRA as her **potassium level** is < 5.0 mmol/L and her **eGFR** is > 30 ml/min/1.73m².
*Digoxin 125mcg once daily*
- This agent is primarily used for **rate control in atrial fibrillation** or as a third-line therapy for worsening symptoms; it does not reduce mortality in heart failure.
- The patient is currently in **sinus rhythm** (regular heart rate) and should receive prognostic-improving medications first.
*Ivabradine 5mg twice daily*
- Indicated only for patients in **sinus rhythm** with a resting heart rate **≥ 75 bpm** despite maximum tolerated beta-blocker therapy.
- This patient's heart rate is **68 bpm**, which is below the threshold for initiating treatment with ivabradine.
*Hydralazine and isosorbide dinitrate*
- Usually reserved for patients of **Black African or African-Caribbean origin** with moderate-to-severe symptoms or those **intolerant** of ACE inhibitors/ARBs.
- There is no indication of drug intolerance or specific ethnicity in this case that would prioritize this combination over an MRA.
*Increase furosemide to 80mg daily*
- **Loop diuretics** are used for symptom relief and fluid management but have no proven benefit in improving **long-term survival**.
- While it might reduce congestion, it does not address the underlying neurohormonal progression of heart failure like an MRA would.
Question 100: A 55-year-old man is diagnosed with hypertension after ambulatory blood pressure monitoring shows a mean daytime blood pressure of 152/96 mmHg. He has no other cardiovascular risk factors and normal renal function. His QRISK3 score is 8%. Lifestyle modifications are discussed. According to NICE guidelines, what is the most appropriate initial pharmacological management?
A. Ramipril 2.5mg once daily
B. Doxazosin modified-release 4mg once daily
C. No antihypertensive medication required; review in 6 months with lifestyle modification
D. Amlodipine 5mg once daily (Correct Answer)
E. Bendroflumethiazide 2.5mg once daily
Explanation: ***Amlodipine 5mg once daily***
- According to **NICE guidelines (NG136)**, patients aged **55 years or older** (or any age if of black African/Caribbean origin) should be started on a **Calcium Channel Blocker (CCB)** as Step 1 treatment.
- This patient has **Stage 2 hypertension** (mean daytime BP 152/96 mmHg), which necessitates immediate pharmacological management alongside lifestyle advice regardless of the **QRISK3 score** or target organ damage.
*Ramipril 2.5mg once daily*
- **ACE inhibitors** like Ramipril are the Step 1 choice for patients **under 55 years** who are not of black African or African-Caribbean family origin.
- While a valid antihypertensive, it is not the first-line preference for a 55-year-old patient without specific indications like **type 2 diabetes**.
*Doxazosin modified-release 4mg once daily*
- This is an **alpha-blocker** and is typically reserved for **Step 4** of the hypertension management pathway in resistant cases.
- It is not recommended as a first-line therapy for uncomplicated hypertension because it is less effective at preventing **stroke** or heart failure compared to other classes.
*No antihypertensive medication required; review in 6 months with lifestyle modification*
- While lifestyle advice is crucial, this patient's blood pressure meets the criteria for **Stage 2 hypertension**, where medication should be offered immediately.
- Review alone is only appropriate for **Stage 1 hypertension** (ABPM 135/85 to 149/94) if the QRISK3 score is <10% and there is no **target organ damage**; this patient is above that threshold.
*Bendroflumethiazide 2.5mg once daily*
- Thiazide-like diuretics (e.g., Indapamide) are generally used at **Step 2** (in combination) or as an alternative to CCBs if a CCB is not tolerated or if the patient has **heart failure**.
- **Bendroflumethiazide** is no longer the preferred diuretic class according to modern NICE guidelines, which favor **thiazide-like diuretics** over conventional thiazides.
